Truist Securities Reiterates Buy on Regeneron Pharmaceuticals, Maintains $1045 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst Robyn Karnauskas has reiterated a Buy rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and maintained a price target of $1045.
November 29, 2023 | 6:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Truist Securities analyst Robyn Karnauskas reaffirmed a Buy rating on Regeneron Pharmaceuticals with a price target of $1045.
The reiteration of a Buy rating and maintenance of a high price target by a reputable analyst like Robyn Karnauskas could instill confidence in investors and positively influence Regeneron's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100